Developer docs
API playgroundTry for free, no card

Search company profiles

STERIS

Full company profile

uuid02mb8oo

Namestring
STERIS
Legal namestring
STERIS plc
Websiteurl
steris-ir.com
Company typeenum
Public
Founded yearint
1987
Descriptiontext

STERIS plc (NYSE: STE) is a publicly traded infection-prevention, contamination-control, and sterilization company incorporated in Ireland (registered No. 595593) with its U.S. headquarters in Mentor, Ohio. Founded in 1987 and listed since 1992, STERIS reorganized from STERIS Corporation (Ohio) to STERIS plc (Ireland) in November 2015 via a one-for-one share conversion. The company operates three reporting segments: Healthcare (infection prevention products, surgical support systems, consumables, and services for hospitals and medical device manufacturers), Applied Sterilization Technologies (contract sterilization and microbial reduction services using ethylene oxide and other modalities for medical devices and pharmaceuticals), and Life Sciences (capital equipment, consumables, and services supporting contamination control and sterilization in pharmaceutical manufacturing and laboratory research).

Underlying technology is built around proprietary formulated chemistries (high-performance disinfectants, sterilants, and cleaning solutions) and applied sterilization processes — both protected by domain know-how, regulatory certifications, and validated customer integrations. Manufacturing is distributed across the United States, Canada, Germany, and Finland, and the company is constructing a $600 million Formulated Chemistries Center of Excellence in North Carolina, the largest single-site investment in its history.

STERIS generates revenue through an enterprise B2B model combining capital equipment sales, recurring consumable chemistries, and service contracts, sold via a direct global field-sales force (over 1,700 sales, service, and field-support personnel historically) under quote-based pricing. In Q1 FY2027 the company reported $1.5 billion in revenue (7% growth), and FY2026 revenue from continuing operations was $5.2 billion (+9%). The company has delivered 21 consecutive years of dividend growth, guided to approximately $800 million of FY2027 free cash flow, and authorized a $1 billion share repurchase program.

Short descriptiontext

STERIS plc is a publicly traded global provider of infection prevention, sterilization, and contamination control products and services for hospitals, medical device manufacturers, pharmaceutical companies, and life science research institutions, operating through Healthcare, Applied Sterilization Technologies, and Life Sciences segments.

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersDublin, Ireland
HQ citystring
Dublin
HQ countrystring
Ireland
HQ regionstring
Europe
Markets served

Serves global market

Offices8 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
infection prevention products, sterilization services, contamination control, healthcare sterilization, life sciences equipment
Industry4 codes
PRIMARYHLAHANAB
Sterilization Services & Contract Reprocessing (ETO/Gamma/E-beam providers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYHLAHANAA
Sterilization Equipment & Systems (Autoclaves, Low-Temp, ETO, H2O2, UV)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYEUAKAIAG
Radiation Processing & Sterilization Services (Medical device sterilization, food irradiation, materials modification)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYIMALAIAB
Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers)
NAICS code3 codes
  • Surgical and Medical Instrument Manufacturing339112
  • Surgical Appliance and Supplies Manufacturing339113
  • Soap and Cleaning Compound Manufacturing32561
SIC code2 codes
  • Surgical & Medical Instruments & Apparatus3841
  • Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics2840
Product category
Infection Prevention and Sterilization
No data
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model3 records
1Healthcare Products and Services
TypeHardware Sales
Description

Revenue from healthcare segment including capital equipment, consumables, and services. Q1 FY2027 Healthcare revenue grew 8% to $1.05 billion, with 10% service revenue improvement, 9% consumable growth, and 1% capital equipment increase.

sterisplc.gcs-web.com
2Applied Sterilization Technologies
TypeProfessional Services
Description

Sterilization services segment. Q1 FY2027 revenue increased 6% as reported to $297.6 million, driven by 6% service revenue growth partially offset by 13% decline in capital equipment revenue.

sterisplc.gcs-web.com
3Life Sciences
TypeHardware Sales
Description

Products and services for pharmaceutical and life science research. Q1 FY2027 revenue increased 9% to $146.7 million with 17% capital equipment growth, 8% consumable improvement, and 2% service growth.

sterisplc.gcs-web.com
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales
Pricing details1 tier
1Enterprise B2B pricing
ModelOtherBilling cadenceOther
Notes

STERIS operates as a B2B enterprise company selling infection prevention and life science products. Pricing is not publicly disclosed on investor relations pages and appears to be quote-based for capital equipment and service contracts.

sterisplc.gcs-web.com
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

STERIS manufactures and sells infection prevention products, sterilization capital equipment, consumable chemistries (disinfectants and sterilants), and surgical support systems for healthcare facilities, medical device manufacturers, pharmaceutical manufacturers, and life sciences research organizations. The company also operates contract sterilization and microbial reduction services using ethylene oxide (EO) for medical device and pharmaceutical customers through its Applied Sterilization Technologies (AST) segment.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • Q1 FY2027: Revenue increased 7% to $1.5 billion; constant currency organic revenue growth was 6%
+2 more records
Product overview1 text field

STERIS is a diversified healthcare and life sciences company operating across three core segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment provides infection prevention products, surgical support systems, consumables, and services. The AST segment offers contract sterilization and microbial reduction services. The Life Sciences segment serves pharmaceutical and laboratory applications with contamination control products. The company also manufactures formulated chemistries for infection prevention and has acquired specialized brands including Hausted (patient positioning systems), Royal Sterilization Systems, and Detach AB. STERIS operates globally with manufacturing in the U.S., Canada, Germany, and Finland.

Product and service6 records
1Healthcare Segment Products and Services
CategoryHealthcare Infection Prevention
2Applied Sterilization Technologies (AST)
CategoryContract Sterilization Services
3Life Sciences Segment Products and Services
CategoryLife Sciences Contamination Control
4Formulated Chemistries
CategoryInfection Prevention Chemistries
5Hausted Patient Positioning Systems
CategorySurgical Patient Support
6Royal Sterilization Systems Services
CategoryContract Sterilization Services
Scale indicator13 records

Each record includes

Type, Value, Description, Source

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Sotera Health operates the Sterigenics, Nelson Labs, and Labstat businesses providing contract sterilization (EO, gamma), lab testing, and advisory services to medical device and pharmaceutical manufacturers — a near-direct competitor to STERIS's Applied Sterilization Technologies segment.

TypeDirect peer
Description

Getinge provides sterilization equipment, infection control solutions, and surgical workflow products to hospitals and life science customers globally, directly overlapping STERIS's Healthcare and sterilization equipment offerings.

TypeBroad incumbent
Description

Ecolab is a large diversified provider of water, hygiene, and infection prevention solutions across healthcare, food service, and industrial markets, overlapping with STERIS's formulated chemistries and healthcare cleaning portfolios at a much broader scale.

TypeDirect peer
Description

Stericycle provides regulated waste management and reusable sharps and instrument sterilization services to hospitals and healthcare facilities, overlapping with STERIS's healthcare services and infection prevention footprint.

TypeDirect peer
Description

ASP is a leading manufacturer of sterilization and disinfection products, including STERRAD low-temperature hydrogen peroxide systems and endoscope reprocessors, directly competing with STERIS's sterilization equipment and endoscope reprocessing portfolio.

TypeDirect peer
Description

Belimed designs and manufactures steam sterilizers, low-temperature sterilizers, and washer-disinfectors for hospitals and life science labs, competing directly with STERIS's sterilization equipment business.

TypeEmerging player
Description

Tuttnauer manufactures autoclaves, sterilizers, and laboratory equipment for healthcare, dental, and life science customers, partially overlapping with STERIS's sterilization equipment portfolio, particularly in mid-market and international segments.

TypeBroad incumbent
Description

Danaher operates a diversified life sciences and diagnostics platform including Cytiva and Pall, overlapping with STERIS's Life Sciences segment through bioprocessing, contamination control, and lab product adjacencies at much greater scale.

TypeEmerging player
Description

Bio-Rad provides life science research and clinical diagnostics products, with overlap in lab consumables and contamination control tools that compete with parts of STERIS's Life Sciences offering.

TypeEmerging player
Description

Miele Professional supplies industrial washer-disinfectors, sterilizers, and lab cleaning equipment to hospitals, pharmaceutical manufacturers, and laboratories, partially overlapping with STERIS's reprocessing and sterilization equipment portfolio.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment2 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature2 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles10 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries3 records

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

STERIS

Infection Prevention and Sterilizationsteris-ir.com

STERIS plc is a publicly traded global provider of infection prevention, sterilization, and contamination control products and services for hospitals, medical device manufacturers, pharmaceutical companies, and life science research institutions, operating through Healthcare, Applied Sterilization Technologies, and Life Sciences segments.

What STERIS does

STERIS plc (NYSE: STE) is a publicly traded infection-prevention, contamination-control, and sterilization company incorporated in Ireland (registered No. 595593) with its U.S. headquarters in Mentor, Ohio. Founded in 1987 and listed since 1992, STERIS reorganized from STERIS Corporation (Ohio) to STERIS plc (Ireland) in November 2015 via a one-for-one share conversion. The company operates three reporting segments: Healthcare (infection prevention products, surgical support systems, consumables, and services for hospitals and medical device manufacturers), Applied Sterilization Technologies (contract sterilization and microbial reduction services using ethylene oxide and other modalities for medical devices and pharmaceuticals), and Life Sciences (capital equipment, consumables, and services supporting contamination control and sterilization in pharmaceutical manufacturing and laboratory research).

Underlying technology is built around proprietary formulated chemistries (high-performance disinfectants, sterilants, and cleaning solutions) and applied sterilization processes — both protected by domain know-how, regulatory certifications, and validated customer integrations. Manufacturing is distributed across the United States, Canada, Germany, and Finland, and the company is constructing a $600 million Formulated Chemistries Center of Excellence in North Carolina, the largest single-site investment in its history.

STERIS generates revenue through an enterprise B2B model combining capital equipment sales, recurring consumable chemistries, and service contracts, sold via a direct global field-sales force (over 1,700 sales, service, and field-support personnel historically) under quote-based pricing. In Q1 FY2027 the company reported $1.5 billion in revenue (7% growth), and FY2026 revenue from continuing operations was $5.2 billion (+9%). The company has delivered 21 consecutive years of dividend growth, guided to approximately $800 million of FY2027 free cash flow, and authorized a $1 billion share repurchase program.

STERIS firmographics

Firmographics
Name
STERIS
Legal name
STERIS plc
Website
https://steris-ir.com
Company type
Public
Founded year
1987
Operating status
Operating
Short description
STERIS plc is a publicly traded global provider of infection prevention, sterilization, and contamination control products and services for hospitals, medical device manufacturers, pharmaceutical companies, and life science research institutions, operating through Healthcare, Applied Sterilization Technologies, and Life Sciences segments.
Ownership category
akta.pro rank

STERIS industry classification

Industry
Product category
Infection Prevention and Sterilization
NAICS
Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113), Soap and Cleaning Compound Manufacturing (32561)
SIC
Surgical & Medical Instruments & Apparatus (3841), Soap, Detergents, Cleang Preparations, Perfumes, Cosmetics (2840)
akta.pro industry
PRIMARYHLAHANAB
Sterilization Services & Contract Reprocessing (ETO/Gamma/E-beam providers)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYHLAHANAA
Sterilization Equipment & Systems (Autoclaves, Low-Temp, ETO, H2O2, UV)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Sterilization, Infection Prevention & Medical Disposables
SECONDARYEUAKAIAG
Radiation Processing & Sterilization Services (Medical device sterilization, food irradiation, materials modification)
Energy, Utilities & Environment/Nuclear Energy/Nuclear Materials, Radiation Services & Isotopes (Medical/Industrial)
SECONDARYIMALAIAB
Sterile & Aseptic Medical Packaging (Pouches, Wraps, Sterile Barriers)

Keywords

  • Infection prevention products
  • Sterilization services
  • Contamination control
  • Healthcare sterilization
  • Life sciences equipment

Where STERIS is headquartered

Location

Headquarters

HQ city
Dublin
HQ country
Ireland
HQ region
Europe

Offices8 records

Markets served

STERIS business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Supply Chain, Operations, Personnel, Infrastructure, Technology or R&D, Marketing or Sales

Revenue model

  1. Healthcare Products and Services: Revenue from healthcare segment including capital equipment, consumables, and services. Q1 FY2027 Healthcare revenue grew 8% to $1.05 billion, with 10% service revenue improvement, 9% consumable growth, and 1% capital equipment increase.
  2. Applied Sterilization Technologies: Sterilization services segment. Q1 FY2027 revenue increased 6% as reported to $297.6 million, driven by 6% service revenue growth partially offset by 13% decline in capital equipment revenue.
  3. Life Sciences: Products and services for pharmaceutical and life science research. Q1 FY2027 revenue increased 9% to $146.7 million with 17% capital equipment growth, 8% consumable improvement, and 2% service growth.

Pricing tiers

ModelBillingPrice
OtherOtherEnterprise B2B pricing

Go-to-market motion1 record

Distribution channels2 records

Marketing channels3 records

STERIS product offering

Product offering

Core offering

STERIS manufactures and sells infection prevention products, sterilization capital equipment, consumable chemistries (disinfectants and sterilants), and surgical support systems for healthcare facilities, medical device manufacturers, pharmaceutical manufacturers, and life sciences research organizations. The company also operates contract sterilization and microbial reduction services using ethylene oxide (EO) for medical device and pharmaceutical customers through its Applied Sterilization Technologies (AST) segment.

Product overview

STERIS is a diversified healthcare and life sciences company operating across three core segments: Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. The Healthcare segment provides infection prevention products, surgical support systems, consumables, and services. The AST segment offers contract sterilization and microbial reduction services. The Life Sciences segment serves pharmaceutical and laboratory applications with contamination control products. The company also manufactures formulated chemistries for infection prevention and has acquired specialized brands including Hausted (patient positioning systems), Royal Sterilization Systems, and Detach AB. STERIS operates globally with manufacturing in the U.S., Canada, Germany, and Finland.

Differentiator

Problem solved

Functional benefit

Products and services

  • Healthcare Segment Products and Services
  • Applied Sterilization Technologies (AST)
  • Life Sciences Segment Products and Services
  • Formulated Chemistries
  • Hausted Patient Positioning Systems
  • Royal Sterilization Systems Services

Quantifiable outcome

  • Q1 FY2027: Revenue increased 7% to $1.5 billion; constant currency organic revenue growth was 6%
  • +2 more outcomes

Companies that use STERIS

Customer profile

Segments2 records

Ideal customer profiles2 records

STERIS technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature2 records

STERIS partnerships and signals

Strategic signal

Scale indicators13 records

Recent moves6 records

Expansion highlights4 records

STERIS competitors and assessment

Company assessment

Direct peers

  • Sotera Health: Sotera Health operates the Sterigenics, Nelson Labs, and Labstat businesses providing contract sterilization (EO, gamma), lab testing, and advisory services to medical device and pharmaceutical manufacturers — a near-direct competitor to STERIS's Applied Sterilization Technologies segment.
  • Getinge: Getinge provides sterilization equipment, infection control solutions, and surgical workflow products to hospitals and life science customers globally, directly overlapping STERIS's Healthcare and sterilization equipment offerings.
  • Stericycle: Stericycle provides regulated waste management and reusable sharps and instrument sterilization services to hospitals and healthcare facilities, overlapping with STERIS's healthcare services and infection prevention footprint.
  • Advanced Sterilization Products (ASP, a Fortive company): ASP is a leading manufacturer of sterilization and disinfection products, including STERRAD low-temperature hydrogen peroxide systems and endoscope reprocessors, directly competing with STERIS's sterilization equipment and endoscope reprocessing portfolio.
  • Belimed (Metall Zug Group): Belimed designs and manufactures steam sterilizers, low-temperature sterilizers, and washer-disinfectors for hospitals and life science labs, competing directly with STERIS's sterilization equipment business.

Broad incumbents

  • Ecolab: Ecolab is a large diversified provider of water, hygiene, and infection prevention solutions across healthcare, food service, and industrial markets, overlapping with STERIS's formulated chemistries and healthcare cleaning portfolios at a much broader scale.
  • Danaher: Danaher operates a diversified life sciences and diagnostics platform including Cytiva and Pall, overlapping with STERIS's Life Sciences segment through bioprocessing, contamination control, and lab product adjacencies at much greater scale.

Emerging players

  • Tuttnauer: Tuttnauer manufactures autoclaves, sterilizers, and laboratory equipment for healthcare, dental, and life science customers, partially overlapping with STERIS's sterilization equipment portfolio, particularly in mid-market and international segments.
  • Bio-Rad Laboratories: Bio-Rad provides life science research and clinical diagnostics products, with overlap in lab consumables and contamination control tools that compete with parts of STERIS's Life Sciences offering.
  • Miele Professional: Miele Professional supplies industrial washer-disinfectors, sterilizers, and lab cleaning equipment to hospitals, pharmaceutical manufacturers, and laboratories, partially overlapping with STERIS's reprocessing and sterilization equipment portfolio.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights6 records

Customer concentration

STERIS financial estimates

Financial estimate

Revenue estimate

Valuation estimate

STERIS leadership team

Management profile

Number of profiles

Profiles10 records

STERIS subsidiaries and ownership

Company hierarchy

Subsidiaries3 records

STERIS funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

STERIS M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about STERIS

What does STERIS do?

STERIS manufactures and sells infection prevention products, sterilization capital equipment, consumable chemistries (disinfectants and sterilants), and surgical support systems for healthcare facilities, medical device manufacturers, pharmaceutical manufacturers, and life sciences research organizations. The company also operates contract sterilization and microbial reduction services using ethylene oxide (EO) for medical device and pharmaceutical customers through its Applied Sterilization Technologies (AST) segment.

Is STERIS a public or private company?

STERIS is a public company. It is classified as public and is currently operating.

When was STERIS founded?

STERIS was founded in 1987.

Where is STERIS based?

STERIS is headquartered in Dublin, Ireland, in the Europe region.

How does STERIS make money?

Three revenue lines are on record. Healthcare Products and Services are the primary driver. The others are applied Sterilization Technologies and life Sciences.

Who are STERIS's main competitors?

Direct peers on record are Sotera Health, Getinge, Stericycle, Advanced Sterilization Products (ASP, a Fortive company) and Belimed (Metall Zug Group). Broad incumbents are Ecolab and Danaher. Emerging players are Tuttnauer, Bio-Rad Laboratories and Miele Professional.

Does STERIS have an API?

No public API is recorded for STERIS.

What industry is STERIS in?

STERIS's product category is Infection Prevention and Sterilization. Its primary akta.pro industry code is HLAHANAB, Sterilization Services & Contract Reprocessing (ETO/Gamma/E-beam providers), with a secondary code of HLAHANAA, Sterilization Equipment & Systems (Autoclaves, Low-Temp, ETO, H2O2, UV). Its NAICS code is 339112 and its SIC code is 3841.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
MarketWatchSteris PLC stock underperforms Tuesday when compared to competitorsSteris PLC shares fell 1.46% to $257.41 on Tuesday, marking a second consecutive day of losses. The decline occurred amid a broader market downturn, with the S&P 500 down 1.03% and the Dow down 1.64%.Defense WorldSTERIS plc $STE Stock Position Lifted by Eurizon Capital SGR S.p.A.Eurizon Capital SGR S.p.A. increased its STERIS stake by 3.2% to 101,569 shares in Q3. STERIS shares rose 4.1% to $263.76, and the company reported Q3 EPS of $2.94, beating estimates. A $0.69 quarterly dividend is set for Dec. 17.MarketWatchSteris PLC stock outperforms competitors despite losses on the daySteris PLC shares fell 1.10% to $253.44 on Thursday, marking a second consecutive day of losses. The decline occurred despite a broader market downturn, with the S&P 500 down 0.35% and the Dow down 0.36%.MarketWatchSteris PLC stock outperforms competitors on strong trading daySteris PLC shares rose 2.50% to $254.12 on Thursday, its second consecutive day of gains, while the S&P 500 fell 4.36% and the Dow fell 3.44%. The stock outperformed the broader market on a dismal trading session.The future of tradingSTERIS plc reports results for the quarter ended September 30 - Earnings SummarySTERIS plc reported quarterly adjusted EPS of $2.94 for the quarter ended September 30, beating the $2.68 analyst mean. Revenue rose 8.8% to $1.59 billion, and the company beat earnings expectations. The stock rose 10.2% this quarter.TradingViewSTERIS Plc Profit Rises In Q2STERIS plc reported Q2 profit of $213.7 million, up from $191.9 million a year earlier, with EPS of $2.19 versus $1.94. Revenue rose 8.8% to $1.588 billion from $1.460 billion. The company guided full-year EPS to $11.35–$11.55.MarketBeatSTERIS plc (NYSE:STE) Announces Quarterly Dividend of $0.69STERIS declared a quarterly dividend of $0.69 per share, payable December 17 to shareholders of record November 17. The dividend represents a $2.76 annualized yield of 1.2%, with a payout ratio of 25.1%. Analysts expect earnings of $12.40 per share next year, implying a future payout ratio of 22.3%.MarketBeat8,560 STERIS plc $STE Shares Acquired by Deroy & Devereaux Private Investment Counsel Inc.Deroy & Devereaux Private Investment Counsel Inc. increased its stake in STERIS plc by 51% in Q3, buying 8,560 shares to hold 25,355 shares worth $5.325 million. Analysts rate the stock a Moderate Buy with an average target price of $271.33, and the company reported Q3 EPS of $2.59, beating estimates.MarketWatchSteris PLC stock underperforms Wednesday when compared to competitorsSteris PLC shares closed 17.80% below its 52-week high of $269.44, which the company reached on January 16th. The stock underperformed competitors on Wednesday, with the company's stock down 1.64% while the SPX and DJIA rose.